Initial findings suggest potential benefits
Magnesium-ibogaine therapy in veterans with traumatic brain injuries.
We examined how magnesium, in combination with ibogaine, affects anxiety in veterans with traumatic brain injuries. This was part of a larger study focusing on the wellbeing of Special Operations Forces veterans, who often suffer from mental health issues like anxiety and PTSD after experiencing head trauma.
The study involved 30 male veterans, primarily with mild brain injuries. Researchers used various assessments, including scales for anxiety, to measure changes before treatment and then again one month afterward. The findings were promising, showing considerable improvements in anxiety levels, as well as in depression and PTSD symptoms.
However, it’s important to note that since magnesium was administered alongside ibogaine, we can’t isolate the effects of magnesium alone on anxiety. Although the results were encouraging, we need more controlled clinical trials to fully understand the safety and effectiveness of magnesium treatment on its own.
Overall, while magnesium may play a role in improving anxiety, further research is essential to clarify its specific impact without the influence of other treatments.
Read More
Zinc shows promise for anxiety
Synergistic anxiolytic efficacy exploring the combined effects of diazepam and zinc chloride in wistar albino rats.
We aimed to understand how zinc chloride may help reduce anxiety, particularly when combined with diazepam. In our study, we organized Wistar albino rats into five groups, with each group receiving different combinations of zinc chloride and diazepam. The dosages included two different levels of diazepam (1 and 2 mg/kg) paired with a consistent dose of zinc chloride (10 mg/kg).
To assess the anxiety levels of the rats, we employed four established models: the Elevated Plus Maze, the hole board, the light and dark box, and the mirror chamber. Our observations indicated that when combined, zinc chloride and diazepam produced more potent anxiolytic effects compared to when either treatment was used alone. This suggests a possible synergistic effect that could enhance anxiety relief.
Overall, we found that zinc chloride, especially when combined with diazepam, can significantly improve anxiety outcomes in these animal models. This research opens the door to further studies on zinc's role in anxiety management and its potential as a supplementary treatment option alongside traditional medications.
Read More
Zinc reduces anxiety in treatment
Investigating the effect of zinc supplementation on probability of relapse and mental health in patients with opioid use disorder undergoing methadone maintenance treatment.
In a recent study, we investigated how zinc supplementation could impact anxiety levels among patients undergoing methadone maintenance treatment for opioid use disorder. The research involved a randomized controlled trial with 68 participants. We divided them into two groups: one received zinc supplements along with their usual methadone treatment, while the other group only received methadone.
Our findings revealed some encouraging results regarding anxiety reduction. Specifically, we noted a significant decrease in anxiety levels among those who took zinc, with a marked difference when compared to the control group. This was assessed using the Depression, Anxiety, and Stress Scale 21 (DASS-21), where we observed a notable reduction in anxiety scores following the treatment period.
Overall, it appears that zinc supplementation may contribute positively to reducing anxiety in this particular patient demographic. However, since zinc was combined with methadone treatment, it's essential we approach these findings with caution and encourage further research to clarify the role of zinc supplementation alone.
Read More
Calcium blockers reduce cocaine withdrawal anxiety
L-type calcium channel blockade attenuates the anxiogenic-like effects of cocaine abstinence in female and male rats.
We explored how blocking L-type calcium channels (LTCCs) could influence anxiety-like behaviors during cocaine abstinence in both female and male rats. In this study, rats were trained to self-administer cocaine or saline, followed by a two-week abstinence period. Throughout this withdrawal phase, we examined their behavior using several tests designed to measure anxiety and mood, notably the elevated plus maze and forced swim test, while also checking for changes in their preference for a sweet solution.
Our findings revealed that cocaine-abstinent rats exhibited increased anxiety, as indicated by reduced time spent in open arms of the maze and heightened immobility in the forced swim test. Administering isradipine—a calcium channel blocker—could reverse some anxiety-like behaviors, with varied efficacy based on sex and dosage. For instance, the lower dose effectively reduced anxiety in female rats, while males required a higher dose to obtain similar results. In terms of immobility during stress tests, both sexes benefited from the lower dose of isradipine, while the higher dose affected both groups regardless of their abstinence condition.
This research emphasizes the potential of LTCCs in managing mood-related symptoms linked to cocaine abstinence, though results suggest a more complex relationship that requires further investigation. Overall, our study presents a hopeful look at calcium channel blockade as a possible avenue for treating anxiety disorders that may arise from substance withdrawal.
Read More
High-dose vitamin D reduces anxiety
Effects of an 8-week high-dose vitamin D supplementation on fatigue and neuropsychiatric manifestations in post-COVID syndrome: A randomized controlled trial.
We conducted a study to understand how high-dose vitamin D supplementation might impact anxiety levels, particularly in patients experiencing post-COVID symptoms. In our double-blind, randomized controlled trial, we enrolled 80 individuals dealing with fatigue or neuropsychiatric issues after COVID-19.
Participants were split into two groups: one received a weekly dose of 60,000 IU of vitamin D, while the other group received a placebo. Over eight weeks, we evaluated various outcomes, including anxiety levels using the Depression, Anxiety, and Stress Scale (DASS-21).
The results were encouraging for the vitamin D group. We observed significant improvements in anxiety levels, with a notable reduction reported by participants. However, other measures related to sleep quality, depression, cognitive function, and inflammatory markers did not show similar significant changes.
Importantly, we found that the vitamin D group reported no serious adverse effects, indicating that this supplementation is generally safe. These findings suggest that high-dose vitamin D may offer substantial benefits for anxiety relief in patients recovering from COVID-19, albeit with limited effects on other symptoms.
Read More